Advertisement

Topics

Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates

03:43 EDT 23 Jun 2017 | Cancer Networks

Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Original Article: Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates

NEXT ARTICLE

More From BioPortfolio on "Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates"

Advertisement
Quick Search
Advertisement
Advertisement